This filing is a routine press release with no material trading implications. Monitor the upcoming August 5 FDA meeting for any policy signals, but no immediate catalyst for PVLA shares.
Price Chart
Executive Summary
Palvella Therapeutics announced that its Chief Scientific Officer, Dr. Jeffrey Martini, has been selected to provide public comment at an FDA public meeting on drug repurposing on August 5, 2026. This is a routine speaking engagement with no financial or regulatory impact on the company's pipeline or stock.
Key Facts
- Dr. Martini will provide public comment at an FDA public meeting on drug repurposing on August 5, 2026.
- The meeting is convened by the Reagan-Udall Foundation in collaboration with the FDA.
- No financial data, clinical results, or regulatory decisions were announced.
Financial Impact
None — no financial metrics disclosed or impacted.
Risk Factors
- No material risks identified in the filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335947 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access